0001144204-13-055113.txt : 20131015 0001144204-13-055113.hdr.sgml : 20131014 20131015095651 ACCESSION NUMBER: 0001144204-13-055113 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20131010 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20131015 DATE AS OF CHANGE: 20131015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MISONIX INC CENTRAL INDEX KEY: 0000880432 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 112148932 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10986 FILM NUMBER: 131150632 BUSINESS ADDRESS: STREET 1: 1938 NEW HIGHWAY CITY: FARMINGDALE STATE: NY ZIP: 11747 BUSINESS PHONE: 5166949555 FORMER COMPANY: FORMER CONFORMED NAME: MEDSONIC INC DATE OF NAME CHANGE: 19930328 8-K 1 v357262_8k.htm CURRENT REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 15, 2013 (October 10, 2013)

 

MISONIX, INC.

 

(Exact name of registrant as specified in its charter)

 

New York   1-10986   11-2148932
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)
         
1938 New Highway, Farmingdale, NY   11735
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (631) 694-9555

 

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 1.02Termination of a Material Definitive Agreement.

 

As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2011, MISONIX, INC. (the “Company”) and PuriCore, Inc. (“PuriCore”) entered into a Product License and Distribution Agreement, dated as of July 19, 2011 (the “Distribution Agreement”).

 

On October 10, 2013, the Company and PuriCore entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”). Pursuant to the Settlement Agreement, the Company and PuriCore agreed that the Distribution Agreement was terminated as of October 10, 2013.

 

Except for the survival of confidentiality obligations under the Distribution Agreement, PuriCore and the Company no longer have any other rights, licenses or obligations under the Distribution Agreement.

 

The foregoing description of the Settlement Agreement is qualified in its entirety by reference to the provisions of the Settlement Agreement and Mutual Release attached to this report as Exhibit 10.1.

 

The full text of a press release issued on October 11, 2013 announcing the Settlement Agreement is included as Exhibit 99.1 to this report and is incorporated herein by reference.

 

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit 10.1Settlement Agreement and Mutual Release, dated as of October 10, 2013, by and between PuriCore, Inc. and MISONIX, INC.

 

Exhibit 99.1Press Release of MISONIX, INC., dated October 11, 2013.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: October 15, 2013 MISONIX, INC.
   
   
  By:  /s/ Richard Zaremba
    Richard Zaremba
Senior Vice President and Chief Financial Officer

 

 
 

 

EXHIBIT INDEX

 

Exhibit No.Description

 

10.1Settlement Agreement and Mutual Release, dated as of October 10, 2013, by and between PuriCore, Inc. and MISONIX, INC.

 

99.1Press Release of MISONIX, INC., dated October 11, 2013.

 

 
 

 

EX-10.1 2 v357262_ex10-1.htm SETTLEMENT AGREEMENT AND MUTUAL RELEASE

SETTLEMENT AGREEMENT

AND

MUTUAL RELEASE

 

THIS SETTLEMENT AGREEMENT AND MUTUAL RELEASE (this “Agreement”) is made and entered into, effective as of the date of the last signature affixed hereto (the “Effective Date”), by and between PuriCore, Inc. (“PuriCore”) a Delaware corporation, and MISONIX, INC. (“Misonix”) a New York corporation (collectively, the “Parties”, or each individually, a “Party”).

 

RECITALS:

 

WHEREAS, PuriCore International Limited and PuriCore plc, each affiliates of PuriCore, and Misonix entered into a Share Purchase Agreement and related agreements (the “Purchase Agreement”) to acquire the issued shares of Labcaire Systems Limited, which was a subsidiary of Misonix; and

 

WHEREAS, litigation arose in connection with the Purchase Agreement (the “Litigation”), and in mutually negotiating the settlement of the Litigation prior to trial, the Parties entered into a Product License and Distribution Agreement dated as of July 18, 2011 (which, with its Exhibits and any other claim of obligation between the Parties, is referred to as the “License Agreement”) for the purpose of the license and distribution by Misonix of PuriCore’s Vashe system; and

 

WHEREAS, the Parties dispute certain claims for damages arising from or related to the License Agreement (the “Dispute”); and

 

WHEREAS, the Parties, in order to avoid the expense, time, and risks of continuing the Dispute, have reached a full settlement of the Dispute, and wish by this Agreement to memorialize the terms and conditions upon which the Dispute and any other claim between the parties will be settled and forever discharged;

 

NOW THEREFORE, in consideration of the premises, the reciprocal covenants contained herein, and other good and valuable consideration, the receipt, sufficiency and adequacy of which are acknowledged, the Parties agree as follows:

 

1.            Termination of License Agreement. The Parties accept and agree that the License Agreement has been terminated as of the Effective Date of this Agreement, and, with the exception of any surviving confidentiality obligations set forth in Section 9 of the License Agreement, the Parties no longer have any other rights, licenses, or obligations under the License Agreement, including from obligations otherwise incurred, accrued, or occurring before the Effective Date.

 

2.            Mutual Release.

 

a.Misonix, for itself and its past, present, and future agents, affiliates, principals, officers, directors, managers, employees, parents, subsidiaries, contractors, predecessors, successors, partners, shareholders, attorneys, assigns, and representatives (the “Misonix Releasors”) hereby releases, waives, and forever discharges PuriCore and each of its respective past, present and future agents, affiliates, principals, officers, directors, managers, employees, parents, subsidiaries, contractors, predecessors, successors, assigns, partners, shareholders, attorneys, and representatives, including but not limited to PuriCore plc and PuriCore International Limited (collectively, the “PuriCore Releasees”) from any and all claims, demands, damages, actions, causes of action, liabilities, proceedings, suits, or costs (including attorneys’ fees and court costs) of any nature, whether known or unknown, contingent or liquidated, and/or mature or not yet mature (the “Misonix Claims”), that the Misonix Releasors, or any of them, ever had, or may have, against any of the PuriCore Releasees, including but not limited to (i) any Misonix Claims that in any way relate to the License Agreement or intellectual property, products, or technologies sold and/or licensed pursuant to the License Agreement; and (ii) any Misonix Claims that relate to Note payments due under the Purchase Agreement.

 

 
 

 

b.PuriCore, for itself and its past, present, and future agents, affiliates, principals, officers, directors, managers, employees, parents, subsidiaries, contractors, predecessors, successors, partners, shareholders, attorneys, assigns, and representatives, including but not limited to PuriCore plc and PuriCore International Limited (the “PuriCore Releasors”) hereby releases, waives, and forever discharges Misonix and each of its respective past, present and future agents, affiliates, principals, officers, directors, managers, employees, parents, subsidiaries, contractors, predecessors, successors, assigns, partners, shareholders, attorneys, and representatives (collectively, the “Misonix Releasees”) from any and all claims, demands, damages, actions, causes of action, liabilities, proceedings, suits, or costs (including attorneys’ fees and court costs) of any nature, whether known or unknown, contingent or liquidated, and/or mature or not yet mature (the “PuriCore Claims”), that the PuriCore Releasors, or any of them, ever had, or may have, against any of the Misonix Releasees, including but not limited to any PuriCore Claims that in any way relate to the License Agreement or intellectual property, products, or technologies sold and/or licensed pursuant to the License Agreement.

 

3.            Representation of No Assignment. The Parties expressly warrant and represent to the other that they have not assigned, pledged, or otherwise in any manner whatsoever, sold or transferred either by instrument in writing or otherwise, any right, title, interest or claim that it has or may have by reason of the above-described matters or any matters arising out of or related thereto.

 

4.            No Admission. This Agreement is not and shall not in any way be construed as an admission of liability by either Party of any violation of law, regulation, or contract, with all allegations of liability or damages still expressly denied by the Parties. This Agreement simply represents the Parties’ agreement to settle their disputed claims to avoid the expense and uncertainty of litigation.

 

5.            Multiple Counterparts. This Agreement may be executed in multiple faxed or e-mailed counterparts, each of which shall constitute an original and all of which shall constitute one agreement.

 

6.            Severability. All of the provisions of this Agreement are intended to be distinct and severable. If any provision of this Agreement is declared to be invalid or unenforceable in any jurisdiction, it shall be ineffective in such jurisdiction only to the extent of such invalidity or unenforceability. Such invalidity or unenforceability shall not affect either the remainder of such a provision, to the extent it is not invalid or unenforceable, or any other provisions hereof, nor render invalid or unenforceable such provision in any other jurisdiction.

 

7.            Authority to Act. Any person executing this Agreement in a representative capacity on behalf of either Party hereby represents and warrants to the other Party that he has the express or implied authority to enter into this Agreement on behalf of such party which he represents.

 

 
 

 

8.           Jointly Drafted. This Agreement has been fully and freely negotiated by the Parties, shall be considered as having been drafted jointly by the Parties, and shall be interpreted and construed as if so drafted, without construction in favor of or against any party on account of its participation in the drafting hereof.

 

9.           Governing Law. This Agreement shall be governed by and construed in accordance with the law of the Commonwealth of Pennsylvania (other than its principles of conflicts of laws). In the event of any litigation relating to or arising from this Agreement, the sole and exclusive venue for such litigation shall be in the United States District Court for the Eastern District of Pennsylvania, or in such cases where there is no federal court jurisdiction, the Chester County Court of Common Pleas. The Parties consent to the respective exclusive personal jurisdiction and venue of the foregoing courts.

 

10.           Entire Agreement Regarding Settlement. The Parties understand and agree that the terms and conditions of this Agreement constitute the Parties’ full and complete understanding, agreement, and arrangement regarding this subject matter, with no other or prior agreements, covenants, promises, or arrangements other than those set forth herein. This Agreement shall not be amended, supplemented, or modified except by a writing signed by all of the Parties hereto.

 

IN WITNESS WHEREOF, and intending to be legally bound, the Parties have caused their respective authorized representatives to execute this Agreement, effective as of the Effective Date.

 

 

PURICORE, INC.   MISONIX, INC.  
           
           
By: /s/ Michael R.D. Ashton   By: /s/ Michael A. McManus, Jr.  
Name: Michael R.D. Ashton   Name: Michael A. McManus, Jr.  
Title: Executive Chairman   Title: President and CEO  
           
Date: October 10, 2013   Date: October 10, 2013  

 

 
 

 

EX-99.1 3 v357262_ex99-1.htm PRESS RELEASE

 

 

 

Misonix, Inc. Terminates Agreement with PuriCore

 

 

Company Contact: Investor Contacts:
Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz
Misonix, Inc. Lytham Partners, LLC
631-694-9555 602-889-9700
invest@misonix.com mson@lythampartners.com
www.misonix.com www.lythampartners.com

 

FARMINGDALE, New York – October 11, 2013 – Misonix, Inc. (Nasdaq: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, announced today that Misonix terminated its Product License and Distribution Agreement (“Agreement”) with PuriCore, Inc. for the sale of PuriCore’s Vashe System. Misonix and PuriCore have signed a Settlement Agreement resolving all issues.

 

As a result of the termination of the agreement, Misonix will no longer be obligated to pay the remaining minimum gross profit balance of $1.3 million. The Company previously recorded in fiscal 2013 all appropriate amounts.

 

Michael A. McManus Jr., President and CEO said, “We are pleased to place this matter behind us and move forward with our core business. We will continue to look for appropriate add on products to purchase or distribute that are synergistic to the core procedures and to our surgeons in the spine and wound care businesses.”

 

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

 

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

 

###

 

 
 

 

GRAPHIC 4 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,# M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_ MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!=`;\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**BNR0$'/+5Q?BO MX]^%/`NORZ7JVK?9+Z)%=HOLT\@"GH`O^@^/_`*Y_P#C=+_PU3X"_P"A@_\`)*Y_^-UR M?VS@/^?\/_`E_F=?]EXW_GS/_P`!?^1Z117F_P#PU3X"_P"A@_\`)*Y_^-TG M_#5'@+_H/C_P"N?_`(W1_;.`_P"?\/\`P)?YA_9>-_Y\S_\``7_D>DT5YM_P MU1X"_P"@^/\`P"N?_C=+_P`-4^`O^A@_\DKG_P"-T?VS@/\`G_#_`,"7^8?V M7C?^?,__``%_Y'I%%>;_`/#5/@+_`*&#_P`DKG_XW2?\-4>`O^@^/_`*Y_\` MC=']LX#_`)_P_P#`E_F']EXW_GS/_P`!?^1Z37GG@'_DNGQ%_P![3/\`TF-1 M?\-4^`O^A@_\DKG_`.-UQ7@K]I'P99_&'QS=R:VJP7IL#"YM+@[]D!5N!'D8 M/K7GXW-\"ZM!^WAI)_:7\D_,[<+EF-5&O^YE\*^R_P">'D>^CH**\W/[4_@+ MOKXS_P!>5S_\;K2\(?'[PCXV\16^EZ9J_P!JOKK=Y47V6=-VU2QY9`!A5)Y/ M:O2AFV"E)0C6@V]$E)7;^\\^66XN,7*5*22UORO_`".VI&.%)/84M%>@SC.( M_P"$COG^/B:*9@-._L#[=Y>T9\X7(3=GK]WC'2NWKSS_`)NE7_L5O_;P5Z%) M]QL^E>?@)RDZJD[VD[>G8Z\7",5#E5KQ3?K;<7-`.>^:^,?^"C/_``5ZT_\` MX)[?%G0O"MWX#U'Q5)K>D_VHMS!JD=HL0\YXO+*M&V3E,YSWKTC_`()]?\%# M?"?_``4%^&USK.AV\VB:UI$_DZMH=S.LMQ8$Y\N0,H`>-P,A@!R&!P17T=3) M5"\IR@B4G.S'7OFO M5PN28_$X>>+H4FZB2LKO=ZVZVN>1C,^P.%Q,,)7J)5)VLM;N[LMEI?S/ MO^BF0ON]>*?7DIW1ZZ89QUHS[TR7G`-?"G[=G_!;32_V'/VB;[X?7?PZU/Q+ M-965M>?;8=7CMD<3*6"A&C8C&.N>:]#+UTM%ONT>=FF;8 M7+Z/M\9/EC>U[-ZO;9/LS[N!S[T5Y#^PQ^U5!^VG^SCH_P`1+;0[CP[#K,MQ M$+":Y6Y>+R9GB)WJJ@YVYZ<9KUZN;$4*E"K*C55I1;379K1G5AL33Q%*->D[ MQDDT^Z>P49HJ.?.$?$ M?C@Z/?C_@YUT,<'X-ZU^/B&'_ M`.,U]10X*SRM352&&=GKJXK\VCY2MQUD5*;ISQ"NG9V4G^2L?J=1G]*_++_B M)UT/_HC>M?\`A0P__&:N>'?^#FGPA>:HB:M\)_%5C:.P#S6FJV]TZ#N=C+'G MZ;JN?`^?17,\,_DXO\$R(\>Y#)V6(7W27YJQ^H.>]%<9\`_CKX:_:4^$NA>- M/"-]_:.@:_!Y]M,4,;K@E7C=3RKHP964]"#79J,`#K7R]2$H2<)JS6C1]72J MQJ152F[Q:NFNJ849]Z*R?%_BRP\#^&M1UC5;F*RTS2[:6[NKB4X2"*-2[NQ] M`H)J-;I)%3FHKF>QK9[YHK\RO'7_```M&UN:#PY\-_%OB&QB7-[#8 M"=<\.J$.P!ZC=@X["L?_`(B=M#_Z(YK7_A0P_P#QFOJH<#Y].*DL,]>[BOS9 M\G/CW(82<98E?=)_^VGZFT5^67_$3MH?_1'-:_\`"AA_^,T?\1.VA_\`1'-: M_P#"AA_^,U?^HF?_`/0._P#P*'_R1'_$0.'_`/H)7_@,O_D3]3<^]%?`/[+? M_!P)\-OV@/BCI'A'6O"WB#P1?Z[<)9V5W=7$5W8M.YVI&\B89-S$*"4VY(!( MS7W\.@KPLQRK&8"HJ6,IN$GJK]?1K3<]_+84W5P5132T=NG79ZA110WW M37GGI!G'4T9]Z^7/^"E/_!2JS_X)S:1X0N[SPA>^+/\`A+)[F!%@U!+06WDH MC$DLC;MV_'&,8JO_`,$_O^"LGP]_;SDETJSCG\)^-;<,[^']1N$>6>,?\M+> M08690/O``,O<8P3Z:R;'RPGU^-)NE>W,K/[UNON/(>?8!8S^SW52J_RNZ^Y[ M/[SZKHS0#GOFD<94CUKS#UQ<^]&[)QG)KY'_`."DG_!4ZP_X)T^)/"FG7G@N M_P#%C>*;:XN%D@U)+06WDLBXPR-N)W^V,5WG_!/#]M6V_;X^!TWCNT\.W7AB M*'5;C2OL<]VMTQ,2QL9-ZJHP?,QC';K7H3RG&PP<7PG>K%7<;/3;K:W7N>^4445YYZH$`]>:Q]7\`Z#KMXUS?:-I%[QV8<^((2$WRB/=CR><9SBO0P.18S,HS^JTN=0LWJM/O9Y68\0X/ M+)0^M5?9N>VCUMOLO/J?I"OPG\*G(_X1KP^?^X=#_P#$TO\`PJ;PK_T+/A__ M`,%T/_Q-;ENX?)YS4E>-]4H_R+[D>VL76?VW][.?_P"%3^%1U\->'_\`P70_ M_$TG_"IO"A_YEGP\3_V#H?\`XFMR[8I$S`!G`)`)P"?3-?G;^T5_P7DU3]E' MXKZCX+\;?`?Q!IFKV)WQM_PD4+P7T!)"3POY`#QMCJ.0<@@$$5Z.6A\->'_P#P70__`!-)_P`*G\*?]"UX>_\` M!=#_`/$UX#_P43_X*A^"_P#@GQIVFPZG9S>*/%FL8>TT&RN4AG$`.'N)78$1 MQ@\#()9N`."1YY^PO_P6`U;]OCXIOH'AOX,:S8Z3IX$FL:Y<:[$UII2$':#B M$;Y6/W8U.3R3@`FNV'"^)E@WCXT%[)?:?*E^+N_D<-7BO"T\8L!*N_:O[*YF M_P`$TOF?87_"IO"N/^1:\/\`_@NA_P#B:X'P)\-O#DOQK^($+Z!H;10MIPC0 MV$)5,VY)P-O&37K5H28%)ZUY_P"`5S\<_B,>I+Z8/_)8U\SC<+156@U!?&^B M_DF?3X3%5G1K^^_A75_SP.C_`.%4^%#R?#7A_)_ZA\/_`,35C2OA]H&AZA'= M66B:/:746=DL%E''(F00<,`",@D?0U\E>(_VJO&'Q,\>:;>Z'K.E^&--U"[D M3PQ8R6<]X^LHMX]DLUV$NH21)+&["**.1DB`Y7RF-"*J2@M^VS_ M`*ZK8\'#YT\1-THR>W5[K^NCW6NQWE%%%0=1YY_S=*O_`&*W_MX*]#/0UYY_ MS=*O_8K?^W@KT,]#7FY?O5_QR.W&[4_\,?R/Q6_X.6.?VN/`0/\`T*`_]+9Z M^/?V5_VBO%?[$?Q_\/\`C/1Y+O3[B$0O?6Q3='JNFS;6:-DW*)%=/F0[AA@I M!!&:^PO^#E@D?M<>`O\`L41_Z6SUU?Q3_P"">=A^T]_P1U^%/Q'T&!XO'_@/ MP>)@8HGE?6M/C>5FM65`6+I\S1L`<' M$]1BU70->MQ<6EPG!(/5&'574Y5E/(8$&NDUS5;?0M(N;Z\N(;6TLXFGGGF< M)'#&H+,[,>`H`))/0"OP<_X(S_\`!1G4/V1?C58^#=:G:Y^'7CB]C@N(I9E1 M-&NY"$2\1G(5$.5649`(PWWEPWO/_!?;_@HI?/X@N_@9X4NOLVGQP1S>++ZW MN$8W98!TL1M)*H!AI`V"V57&W);\\Q7`6+AG"RRF[QE[RE_=ZM^:V?GY,_1< M+Q]A9Y/+,*BM.-HN/]YK2WD]_)7ZH^7/^"IO[;.I?M^?M27P\/WUYJG@3PL) MH?#EK'"8D:*./?<7I3)R7V,V\X/EJO"\BI?^"(1S_P`%-/AT>N8]0_\`2*:O MH[]E_P#X)ZZ?\"_^"3_Q4^+WB"W:;QOXU\$7K:?'/`T9T73I$X4*X!\V8`,S M=-A55)&2WSE_P1`_Y28?#D^L>H_^D4U?I_U[!RR3&X+`1_=T(2A?NU'5_?UZ MN[ZGY9+"8N&>8'&8Z5YUYQG;LG+1?=TZ+3H?T&P?='TJ2HX/NCZ5)7\Z1/Z2 MCLAL@R!7X)?\%^O^4DVO?]@/3/\`T4U?O<_2OP1_X+]?\I)M>_[`>F?^BFK] M$\,?^1T_\$OSB?FGBM_R)E_CC^3/TL_X(/?\HT/!0]+O4?\`TLEK[#KX\_X( M/?\`*-'P7_U^:C_Z62U]AU\MQ'_R-<3_`(Y?FS[#AE_\)&&_P1_)!6+\0[N2 MQ\$:U/&Q66'3[B1&]"(V(/YUM52UVRCU/3+FUGSY5U"T+XZ[6!4_H:\=-*2; M[H]BM=P:1_-=_P`$\?AYHOQH_;:^&7ACQ3I\6M:%KVL+;ZA:3,P2Z0QR,0Q4 MANH!X(K]Q$_X(Z_LSL,GX1Z#D_\`3>Z_^.U^%GQL^%'CC]A/]I;5=*!UK0-: M\(:E)_96M6T$UKYZ`D17$$CJI(9"/F&1R<$CFM(_\%)/C\<'_A<7Q&R?^HQ+ M_C7]#9_DF.S>I2Q>5XOV<.5;2DK];^[Y/KJ?SKP]GF!R>G5PF9X3VD^=[J+M MHM-?/L?N%_PYS_9FZ_\`"H]!S_UWNO\`X[7QS_P4R_X(F7GB[XA^"[3]GKX> M:)H>EBSNCKER^I>1;K+OC\DOYLA8D+YGW%/4Y[5\!#_@I'\?C_S6+XC?^#B7 M_&KFB_\`!3?]H31;Z.Y@^,/CTR1,&`GU`W"-@]"D@92/8BO,P7"?$6$K+$0Q ML9M7LI2FXZJVJ/3S#B[AW&47AYX-P3:NX*"EH[Z.Q^W'_!+/]DWQ%^Q-^R=9 M>!?%-]I]_K$.I7=^[65PT]O$LS!@BLR(>""2,8R3R:^EXVW(#ZU\O_\`!)O] MK[6_VU/V0M*\5^)TMO\`A)+&]N=(U*2W01QW,D)4K-L'W"Z.I(&!G)``Q7U` MAR@-?C>;K$+'UEBW>IS/FMM>^MO(_9\E^K_4:/U2_L^5 M2J^8X>_\\/\`TI!GCMEU=_W)?^DL_$/_`()F?";P[\*]LI69$G5;:9U!*D,,,JG@CI7[4_\.;?V9O^B2Z/G_K]O/\`X]7X\_\` M!''_`)29?"G_`*_KK_TBN*_HGQW[U^D^)F9XS#9E3CAZTH)P3M&37VI+HUV/ MS'PORO!XG+:L\12C-J;5W%/[,7U3[GR]_P`.;/V9_P#HDNC?^!MY_P#'J9])\E^OW6_E7YS_K!FEU_M-3_P`# ME_F?I$N'\L2=L/#_`,`C_D?RQVA&A_%*'[.#&+'7$\D*3\FRY&T>O``K^IZW ME,UI$YZNH)_*OY8+S_DJ,W_8#?'>D1ZOH[^+/,@(^2XT^8 MV4/[Z"0W;J?@/$>35, MSXIJX6C+EDXIIO:\81?3;U/6_P#@D%_P5XL?VC_#=A\/OB=KUI;_`!.A((@/E`<-M:YQG#7\Z'_!1O_@GIKO\`P3V^ M+=KI\E_=:WX9U?-SHNM+:R0'Y6_U,KX""Y7@_NV.1AL+TK[$_P""3W_!:O5[ M[Q+HGPM^+UTNI1W[?9='\575U'#+`PX2&]>1E$@/190=Y.`0Y.1\SQ)P?2KT M'G&2/FI2]YQ6EN[CMHNL79KI?I]3PUQG5P]=9-G:Y:L7RJ3V?;FWWZ2U3ZV, M_P#X.:R3\1_A"?\`J&:E_P"C8*^B?^#?]C=J/_HNVKYS_`.#F-S-X M_P#A`YWTO\`Z`:_EL\"?\E8T'_L.6W_ M`*4K7]2?BK_D6]0_Z]I?_0#7\MG@3_DK&@_]ARV_]*5K]=\+_P"%C/2/Y3/Q MOQ5_CX/UE^<#^J!/]8?H*?3$_P!8?H*?7Y$?L:V"O!_^"@/[#?A7]NGX+7OA M_6K*`:_9023:!J@?R9]-NBOR_O`K$1,0`ZE6!';(!'O%&*WPV*JX>K&O0DXR MB[IHPQF$I8FC*A7BI1DK-,_F$\0^&?B3^PK^T,EK>_VEX,^(/@VX$L$T3;2C M?PR1MRLL$B]^5=20>XK]@/"O_!<'P#+^P)<>/M0U>Q3XD65M_9TWAX6V)Y=7 M*'84@\S)MF(WEPX4(&!(;Y:W/^"[7P@^&'BG]D'4O%?CA&L_$7AQ/+\-ZA9O M#'?274APMJ!(5\V)^6=`20%+*,BOP>V_O`<@,!C=Z5^[8'"X3C#!T\3BH.%2 ME*S:VDNJ3>O+Y='IJ?@6/Q.,X/QM3"X6:G3JJZ3WCV=MN9=^JUT/;_A'\*_B ME_P5`_:JDB#W7B+Q7X@G6]UW5+A]EMIUL&`>1WP5BC1?EC0*>=JJIZ5_09^S M)^S9X2_91^$&E^#/!>EQZ9I.FKEB3OGO)3]^>9\9DD8\EC[````#Y._X($^- MOAMXA_9)?3O!FCC0O%.EW6SQ6L]S%/>:C<[?ENB0=X@89$895"X91G!8_>D> M=G/45^=\<9_7Q6*_L_D=.E1=E'OYM+3;;LC]%X#R&AAL,LPYU4JU=7+>WDF] M?45/NBO//`6X_&[XCX^]OTW'_@,:]$KSSP#_`,ET^(O^]IG_`*3&OS/'_P`6 M@O[S_P#2)GZ?@]*5?_"O_2X'D_CO]D#QCHOBZ]B^'GB73M&\*Z]<_;+^UU". M*>?3)6N#<.;`M:R>6OFLTRH[,J2L2H4'%>Y_"'X5Z5\&/`FG^'=%%Q]@L%8^ M97EDD9G9CU9C]*ZA>@HKVZV*J58*$NGEJ_5]?F>'A\#2H MS=2&[\W9>G;Y!1117.=IYY_S=*O_`&*W_MX*]#/0UYY_S=*O_8K?^W@KT)SA M2?2O-R_>K_CD=N->E/\`PK\C\5_^#E@Y_:X\!#KCPB/_`$MGK]%_^"3"%_\` M@FE\'@#AO^$?CYP,C]X]?)W_``6^_P"">OQ>_:]_:/\`"FO?#[PLNNZ1I?AS M[!\0:# M]?@E_P`%^O\`E)-KW_8#TS_T4U?O7.H8+G/%?DA_P5U_X)C?&[]J;]MK5O%W M@?P='K/AZYTNPMH[MM5M+I3::G434E"*::LTTEHTPKSK]J MW]H&S_98_9^\5_$'4--O-7L_"MC]LEL[5E6:X&]4"J6X'+`Y/8&O1:X3]IGX M'V7[27P%\7>!-2G:WL_%6ES:>TRKN:!F7Y)`.Y5PK8[XKSZ'LO:P]O\`!=7] M+Z_@>CB_:^PG[#X[.WK;3\3X@_9._P""Z7A[]J[]H5O"WBGPKX7^'_A"/39[ MT:IKVMQN6F1HPD?SHD:E@S'&2?EX[U]5C]JK]GLYS\0O@_D?]1G3_P#XJOQ_ M\:?\$%?VE/!FN7$.E:+HGB2VC*3-&RYZE3G'J:QC_`,$3 MOVJ,\>!)?_"FLO\`X_7ZMC.&>'<1453!XZ%*%E:/.OO?,[GY'@^)>(Z%/V6+ MP,JL[N[Y']RY5:Q^S7_#5/[/?_10O@__`.#C3_\`XJOS;_X.%?BQ\/OB98?" ME?`?B'P?KOV*;4C>?V%>6]QY(9;?9YGE$XR0V,^AQ7A/_#D[]JG_`*$27_PI MK+_X_5C2?^"&?[4'B&^2"Y\(6-DJL!YU_P"(K5HH\]_D=V_(5U9)DV397C88 M[^T82Y+ZJ:Z-OJ"_L^4>>VO++HT^J\C[U_X-OT*?L0>)&( M/S>,;H@^O^C6U?H5']P5\^?\$U/V+7_86_99TKP3=ZE;ZKK4US-J>K75NK"" M2YE(RL>[!V(JH@)`)VYP,X'T&HPH'I7YEQ#C*>*S2OB*+O&4FT^Z[GZCPS@Z MN$RNAAZRM*,4FNS["U\Y_P#!6F)I_P#@G)\857)(\.R-QZ!T)_05]&5Q/[0O MP@L?C]\$?%?@C4Y'BLO%>F3Z9+*@RT/F(5$@')K2)R(=0TW6H;?SE[,4F:-D)')'./4UB_P##DW]J MD/^%N_#7C_J9;/_`..4R7]N#X,>6X'Q;^&K M$J>/^$DLSV_ZZ5^*G_#DW]JC_H1)?_"FLO\`X_3O^')W[5*Y_P"*%E_\*:R_ M^/U\Y_J7DB=UF4/_``*/^9]%+C//FK?V=/\`\!G_`)'S`Q%Y\3R8B)!/KG[L MJ00^ZZX(/3!R/SK^J"U0QV,*MU5%!_*OQ/\`V1_^"!OQ=U7XQZ!J7Q*MM%\* M^%=*OX;^]C&HQWE[>K$X?R8TBRJERH!9F&`2<$X%?MJ/F4'UH\2,XP>,JT*6 M#J*?(I7:U6K5M=MD;>&>48S!T\16Q=-PYVK)Z/1.^F]KL6@]#10>AK\S9^HG MY6_\'.?_`"(_P<'?^TM2_P#14%=7_P`&TH)_9B^(8/7_`(2L?^D<-=1_P75_ M8O\`B5^V/X;^&UK\._#P\03Z!>WTU\#>P6H@62.%4.974')5NF3Q6_\`\$/_ M`-DOXA?L@?!#QAHGQ$T$:#J6K^(%OK6(7D-SYD/V:--V8F8#YE(P3GBOT:KF M.%?!T,'[2/M%._+=9?:"I/W;E0/GB'03*,?W@O4_O/BLGQSX(TCXB>$ M=1T/7=-L=7TC583;W=G=PK+#"/Y=:^=X3UN:D[TW\4>C7Z/S M7ST/I^)^%,)G%!QJJU1?#+JO\UY?=J?S(_$O]I7QA\9?AIX0\+>)M6FUNQ\# M"XCT>>Y8R74$$WEY@:0G+QJ8ALSRH)&<8`_8[_@W,_Y1_P!Y_P!C=J/_`*+M MJ^8_V[O^#?SQ3X9\;C6/@5!'X@\/:G*2^@WE_'!=:,3SB.65@LL/IN.]>GS# MD?:G_!%K]FKQO^R9^R3<^$_'^C?V%KLWB*]OUMA=17(,,D<(5]\3,O)1N,Y& M*^_XQSS*<9D,(X"<4W-/DT33?,W[N^^_3JC\]X,R/-,%G\I8^$FE!KFWBTK) M>]Z:);]T?7U%%%?CA^UF?XJ_Y%O4/^O:7_T`U_+;X$!_X6QH/7_D.6W_`*4K M7]2?B6)[C1+J)`6>:%T4#N2I`_4U^"GA#_@BO^TKI?Q!TF_G^'J+:VVK07,C MC6[`E8UG5BV/.S]T$XK]0\.Q/7/-25^7GZLGH&<=37G7[3_`.TWX1_9 M.^$NI>,O&6HK9:18IM1$P]Q>S$'9!"G5Y&(P!T'))`!(]"GR%)YX&>.M?DY_ MP4V_9]_:Z_;Z^(+6%A\.YM$^&^@SL=)TMM?L%DO'&0+NY`FPTA!^5.1&#CEB M37M9!EU#&XR-+%U8TZ:UDY24=.ROU_!'@\1YI7P6#E/"4I5*KTBE%RU[NW3\ MSXR_:<_:>^)O_!5S]J+2[:UTZ\N9;ZY:P\+^&;20O#IT3'DD]#(5&^69N``> MBJ!7Z'Z7_P`&]O@J7]C;_A%[K4MOQ9D/]H'Q2@8PQ7>W'V3R_P"*S'W>F\DE M\Y^6N@_X)!_\$BQ^R59Q_$#XB6EK<_$RY#):6899X/#L)!!",,JT[C[SKD*/ ME4_>)_0&)!@_*!SZ5]=Q)QC[*I3P.1R]G2I6UC]J2\^J[WT;U=SX[AK@SV]* MIC<\CSU:O272+_*7;^562L?S2Z1K/Q6_X)G?M32E6O/"'CSPK)YUE`R"/8@JPX_\)_M^_#87&G[=%\9Z3$O]N:#+*&EM&/ M'G1$_P"MMV/1P,C.&P>O!?\`!5[_`()3Z1^W%X9E\3>&TLM&^*6D6VVTO'7R MX-:B49%K"O!:6=["!%=V3EV%S?AO,GAJ5.=7"R=_=3DTMKJRTDNO1[H_<6)MR`YS7GW@'_DNGQ%_P![ M3/\`TF-;WPB\4ZUXQ^'>DZCXA\-W/A+6[F$&^TF>ZANFLI>C*)8F9)%SRK`\ M@C(!R!@^`?\`DNGQ%_WM,_\`28U^)YA'EK4(OI-^?V)]C]SP,N:A6EW@O_2X M'H8Z"B@=!17I'$%!KRO^U/BO_P`^7AC_`,!3_P#)=!U3XKX/^@^&_P"'>NT&J?%<9_T+PSS_`-.Q_P#DNO/P M&;I.J_8U/CE]E]SLQN6.U/\`>P^&/VD>J45Y7_:OQ7_Y\?#'_@*?_DNC^T_B MO_SY>&?_``&/_P`EUZ']L_\`3FI_X`SB_LQ_\_8?^!(]4HKRK^T_BO\`\^7A MG_P&/_R72_VI\5_^?+PQ_P"`I_\`DNAYS_TYJ?\`@##^S'_S]A_X$CU2BO*S MJGQ7/_+EX9_\!C_\ETG]I_%?_GR\,_\`@,?_`)+H_MG_`*J45Y5_:?Q7_`.?+PS_X#'_Y+H_M/XK_`//EX9_\!C_\ MET_[87_/FI_X`P_LQ_\`/V'_`($CU6BO*_[4^*__`#Y>&/\`P%/_`,ET'5/B MN?\`ER\,_P#@*?\`Y+I?VS_TYJ?^`,/[,?\`S]A_X$CU2BO*O[3^*_\`SY>& M?_`8_P#R72_VI\5_^?+PSQ_T['_Y+H><_P#3FI_X`P_LQ_\`/V'_`($CU3-% M>5_VG\5FZV/AD^O^C$?^W=>@>#)-5E\.6[:U';1ZD<^'QK%XGM6OH]/,RBY M>W5@IF"==@8A=W3)Q26GCS1[[QG=^'8=3L9==L+=+NYL%F4W$$+DA)&3J%8@ M@$\$@^AKY_\`BCX]T?X7?\%,?"5_XCU.QT/3]9^'M_IUE>7\ZV]O<72ZA!*8 M!(^%W^6-VTG)'3-)\"_%NE?$_P#X*)?%C5M!O[+7-'LO">AZ5<7ME,MQ;+=+ M->2M!YBDJ7"2*2`3C=SCI7>'Q6\*1?L;^'+#6/%FA)?3W& MI03P76KQ+ M$-&UBQLCK%ZR6MT]Y>*TPS,22PBC!SD?(..N0#[0HS7YT_M?^'O$5]^U9\;M M:T+P#;_$1/"6AZ/>RVLNL75I)9DVTS-Y207,3%F6,L=J.Q\L`8/7O?BWX\FT MO]A7X3>![/Q#K7Q!O_B2+.TO+_26EGU6^TA4^T7T\/DB63*1!8=_S,N\');J M`?;.?>BOBWX%?%R;6_V"?B!X3\0^*]1^'.N_#TW7AMM7U)7BU/2[1\'3KN=) M1&ZO)!)&-YVD[2V5.=O'_LFZA>?#;]K#P1HE[X8\+`>);&]CAU3PWXFGN5F$ M<'F>?=6HO;I90VW`EDVA6D`#DD`@'Z!9S[T9KXT\)Z!X`^+7Q/\`C%G:[XK\2Z1K&L^(]3;3=>CD,>H2QVUKJ$NGW,@;`FW)!;NP<8D')QG-`' MWUFC-?'W[&7QF\1?%S]K35-.\>::-%^(7@_PA_9FOV2*\<4SC4&,-XB'*;)X MMKCRVD4;BN\XP/./`_B9X_V*_@S:ZQKVI:1X%\1>/-2L/%NIQ7\EL1:?:]0\ MF&6Z4[XH9)DAC9@R\87';^]MX; MFRENTA=2DT4X\EALD.W>RD-C:=V!0!ZK\-?VB/`WQDGDB\*>+?#OB*2#_6QZ M?J$4\D7NR*=P'(Y(QR*[/-?(7P'\?:QHW[;VG^%[S7_A_P#$Y]9\-75U>>(M M$T2WL;_1$BFB\NWG>":56BF+$JKA.4R,\BO,_P#A96BZ=_P25\8:/-XAMX_$ ML6HZKIQM&U#&I+>'6I5BA";O-\S84"@<[<8XH`_0FC/;O7Q3^WAX%U;QM^U! M\*M$T;PW:^*;I_"VK2OI-WJ4MG$XCDL\.2D\.60L0,L0-YX].&\'>+=:M_V# M="N=2\0ZOX>T77OB1%I_C.RMM0G$O@'33,8;G3OM+R//"BR1IND9@0MR<;5( M-`'Z'T9[=Z^)/V;?%?AOP'^WO_PA7ASP7!HNDZA87IT[5-/\:2ZA::M;Q+$X MGDL?,=5#4-?U+2/!>M_%/5-,\7:K!>20/ M;Z?_`&A?!8WN0=\$+RI!$S@KA6V[E!H`_0:BOG_X1Z+\$O@Q\4;B+PGX@TW3 MM7;19;RZTNU\12W-F+.-D+WDD)D>-648'F'#%2W7DCYM_9I^/^M:9^U/X>^( M>MV'BO2M&^-5_>Z7J5UJEO=Q:+#&S;M#-HTD2Q*TD483*L?-,^6VD`4`?HE1 M7S-\%OB3H7@O]M[]H/$6E:66ET`V\5_J*0@`V#%]BNPP"<$[1R3S7T=HF MNV?B338+W3[NVO[*Z0207%O*LL4RGHRLI((]P:`.%\2?M=?"_P`&Z_>:5K'Q M!\'Z7J>G2&&ZM;K5H8IK9P`=KJS`J<$'GL:[CP]XCL?%FD6^HZ9>VNHZ?>() M;>ZM9EFAG0]&5U)##W!KY?\`V9_'?@SPQ\9/VB(?$VM^%M-=O'C,4U2[MXF, M?]G6@R1(0=O7VX/O7BWC"XM)/V%/VA]5\++':^!+WQ[%+X4^SRFVL)(C8Y'VN?81(?OC:1A?Q\__9VU_5?C)\7?A]\&=H MW?B5M[)-=-:R"VT4W'0$3PR^>0K.',0)XS0!]XYHKX5\=^,?$'A'P%^UOJ'A M[4=3M+ZP\;6$,MW9LTESI=B]IIPNY80,E#'!)/("H^4Y8#->J_##P+^S_P## MWXA>"[SPKXEL(=?UAVCTI;/Q5<73Z^&B$]#\7_&G79?%>E^$)]"B\VO[=(KJ*Y<3AW4G2DG\,K_`/DLH_J=%*NJ<*D6OB5O_)HO]#2'044` M8`'6BNI'.%!HH/((]:`//#_R=*O_`&*W_MX*]#KG_P#A`Q_PM(>)OM1W#2O[ M,^S^7Q_KO-W[L_AC'XUT%<6#HSINIS+>3:]&=6*J1GR,/`.B?$+3UL]>TC2M;LU<.+ M?4+..ZB#`?>VN",^]'AGP%H_@G2!I^B:9INC6`8O]FL+2.VAR>IVH`,GZ5KT M4`<7-^SA\/YI1*?`_@X3!Q()?[%MMX8'(8'9D$'D'J",UTEIX6L+/7IM52SL MQJ=S$L$MX($%Q+&IRJ-)C<5!)P"<"M"B@#.@\*:?::O>7\-E9PWVHJJW5PEN MBS7(484.P&7"@G`;.,U3TGX::#H%Q9S6&BZ/93:=&\-J]O8Q1-;(YW.B%5!1 M6;DA<`GDUNT4`97_``A&E'4KV]_L[3_MFI1K#>3_`&5/-NT4859&QEU`)P&R M!FL_P7\'/"GPWNKF?P[X9\/:!/>#$\FFZ;#:O.,YPQ102,\\UTM%`'-^+O@_ MX5^(&HVUYKWAOP_KEW9#%O/J&FPW,L'.?D9U)7GGCO6KJ'AFQU2>RFN+.TGF MTYS):R20*[VK%2I:,D90[21E<<$BK]%`&:GA'3H];DU06=F-5EA%N]Z($%P\ M0.1&7`W%03G:3C/:H8/`&BVGAR71XM*TR+29PZR6*6D8MI`Q)8&,#:0Q))XY MSS6Q10!@^!_A9X:^&5K-!X<\/Z)H$-P0TL>FV$5JLA'=@BC/XU?\2>%M.\8Z M5+8:M8V6IV%P,2VMW;I/#*/1D<$'\15^B@#!\$_"_P`._#2PEM/#FA:+X?M9 MV#O#IMC%:([`=2(P`3[FJDWP0\'W/C-?$!A_%YNW? MGWSFNIHH`S[KPM87>N0:I)9V$KP2V'= M`T`W9S-_9NG0VGFG_:\M1G\:MV7@'1].T&XTJ#3--ATRZW^;9QVD:6\N\DON MC`VMN).'_@CX1\(Z/>Z=I/ACPYI5AJ2E;RVL]+@@ANU((*R( MJ@.#D\-D5J:GX)TG6="MM+N],TVZT^T,9AM9K2.2"(QXV%4(VKMP-N!Q@8K5 MHH`Y77/@;X-\5:K)?ZMX3\,ZK?3`>9<7FE03S28&!EV4D\`#DUNZ!X=L?"VE MP6&FVEKI]A:H(X+:VB6*&!!T544`*!Z`8J[10!R6L?`7P3XBU6>^U#P?X5O[ MVY;?+<7.D6\LLK?WF=D))]RZ6%5/L4]LDEMM7&T> M605P,#''&*U:*`.7\._!3PCX,U==0T3POX=T6^"-%]HL=-AMI2C$$J6102I( M'&<<"M.P\$Z5I6L7FI6NG6%MJ6H!1=W<5LB7%UM&%\QP-SX[;B<5JT4`9FG^ M#].T>[N[BSLK.UGU!_-NY(;=$>[?&W?(0,NVWC+9.*R_"OP7\)>!=4N+_1/# M/AW1M0NP1/=6&F06TTV3D[G103D^IKIZ*`.,O_V=?`.J3S3W/@GPA/N:N>,?@OX4^(KVS^(O#7A[7Y+/_4OJ.FPW31